GSK's shingles vaccine approved for use in China in adults aged 50 and above

An exterior view of GlaxoSmithKline (GSK) Asia House is seen in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera - Copyright Loriene Perera(Reuters)

By Reuters

Published on 23/05/2019 - 18:34•Updated 09/12/2019 - 11:07

Comments

(Reuters) – GlaxoSmithKline Plc said on Thursday its shingles vaccine had been approved for use in China in adults aged 50 and above.

Shingrix, which has already been approved for use in the European Union, the United States, Canada, Japan and Australia, brought in 357 million pounds in the latest quarter.

The company said the vaccine will be introduced in phases, starting in 2020 to ensure reliable supply to all countries, where it has been launched.

(Reporting by Samantha Machado in Bengaluru; Editing by Anil D’Silva)

Comments